NASDAQ$PAYS

Paysign Inc · Q3 2022 earnings

Q3 2022 earnings · · Investor relations

Briefing

Paysign delivered revenue growth and returned to profitability.

Paysign reported impressive revenue growth and a return to profitability in Q3 2022, with gross margins increasing to 54%. The company benefited from organic growth in plasma centers, a full quarter of revenue from newly onboarded plasma donation centers, and increased activity at border locations due to a preliminary injunction.

  • Paysign delivered impressive revenue growth in Q3 2022 and returned to profitability.
  • Gross margins increased to 54%.
  • Benefited from a full quarter of revenue from 49 plasma donation centers onboarded late in the second quarter.
  • Activity at border locations started to ramp up late in the third quarter due to a preliminary injunction.

Headline financials

Total Revenue

$10.6M

Previous: $7.77M+36.4%
EPS (adj)

$0.02

Previous: -$0.01+300.0%
Gross Profit Margin

54.0%

No prior period
Capital Expenditures

-$75.7K

Previous: -$190K+60.1%
Free Cash Flow

$776K

Previous: -$461K+268.6%
Net Income

$852K

Previous: -$271K+414.4%
Operating Income

$623K

Previous: -$277K+324.8%
Gross Profit

$5.75M

Previous: $3.97M+44.8%
Cash & Equivalents

$8M

Previous: $70.2M-88.6%
Total Assets

$114M

Previous: $83.2M+37.5%
Stock-Based Comp

$566K

Previous: $604K-6.2%

Revenue & EPS history

Paysign · Revenue · Quarterly

$10.6M

Q3 2022+36.4%vs Q3 2021
Beat estimate in 9 of 15 quarters(60%)
ActualEstimate

Forward guidance

Paysign expects total revenue for 2022 to be $38.15 million to $38.35 million, representing growth of 29-30% over 2021. Full-year gross profit margins are expected to be approximately 56.0%, with operating expenses expected to be between $21.00 million and $21.25 million. Adjusted EBITDA is expected to be $5.50 million to $5.60 million.

Tailwinds

  • Plasma business continues to rebound from the negative impact experienced from COVID-19.
  • Continued addition of new plasma centers.
  • The preliminary injunction preventing the United States Customs and Border Protection from continuing to enforce its ban on plasma donations by Mexican nationals.
  • Inflationary pressures driving individuals back into plasma donation centers.
  • Growth opportunities in pharma business as we continue to launch new programs and build a significant pipeline of new business well into 2023.

Headwinds

  • One of our plasma customers consolidating and closing 13 of their centers.
  • Two pharma prepaid programs ending in mid-November.
  • Operating expenses expected to be between $21.00 million and $21.25 million as we continue to invest in people and technology and experience higher costs in insurance, travel and entertainment and other inflationary pressures.
  • Depreciation and amortization is expected to be approximately $2.91 million.
  • Stock-based compensation is expected to be approximately $2.28 million.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q3 2022

Historical avgQ3 2022

+16.3%

Avg return

Earnings day

+5.5%

Avg return

5 days after

+9.6%

Avg return

30 days after

43%

26 / 60 earnings

Positive

+900.0%

Q3 2011

Best reaction

-29.6%

Q4 2015

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-12.6%-12.0%
Q4 2025+37.3%+52.8%+65.0%
Q3 2025+0.2%-8.8%+0.4%
Q1 2025+3.0%+22.9%+81.9%
Q4 2024-8.5%-14.5%-8.1%
Q3 2024+10.9%+8.7%-7.9%
Q2 2024-6.7%-14.4%-9.2%
Q1 2024-0.4%+5.4%-7.6%
Q4 2023+20.5%+10.2%+31.9%
Q3 2023+18.1%+21.6%+18.1%
Q2 2023+6.4%+8.6%+16.0%
Q1 2023-1.8%-4.5%-20.7%
Q4 2022+4.2%+7.6%+0.3%
Q3 2022-10.4%+8.9%+16.5%
Q2 2022+7.4%+15.3%+33.5%
Q1 2022-26.2%-20.2%-2.4%
Q4 2021-6.6%-16.6%-21.4%
Q3 2021-9.0%-14.6%-32.8%
Q2 2021-2.4%+5.6%+16.7%
Q1 2021-11.4%-10.8%+0.0%
Q4 2020+11.7%+5.1%+0.8%
Q3 2020-26.8%-20.6%-7.7%
Q2 2020-18.9%-30.5%-45.3%
Q1 2020-5.5%-13.0%-0.4%
Q4 2019+27.3%+82.9%+102.7%
Q3 2019+13.2%+17.1%+3.9%
Q2 2019+2.5%+6.3%+2.7%
Q1 2019-11.7%-6.7%+18.2%
Q4 2018-1.7%-7.5%-1.0%
Q3 2018-0.5%-1.6%-6.3%
Q2 2018+10.1%+2.7%-2.7%
Q1 2018-0.9%+18.8%+23.1%
Q4 2017+19.0%+20.6%+44.3%
Q3 2017+7.9%+19.3%+15.8%
Q2 2017+2.8%+9.4%+0.0%
Q1 2017-8.7%-6.5%-6.5%
Q4 2016+4.7%+0.0%+0.0%
Q3 2016+34.9%+73.7%+73.7%
Q2 2016+0.0%-5.0%-20.0%
Q1 2016-23.2%
Q4 2015-29.6%
Q3 2015-12.0%
Q2 2015+6.3%
Q1 2015+4.3%
Q4 2014+71.2%
Q2 2014-16.7%
Q1 2014+0.0%
Q4 2013+23.4%
Q3 2013-17.9%
Q2 2013-16.6%
Q4 2012-4.3%
Q1 2013-4.3%
Q3 2012+18.5%
Q2 2012+0.0%
Q1 2012+0.0%
Q4 2011+0.0%
Q3 2011+900.0%
Q2 2011+0.0%
Q1 2011+0.0%
Q4 2010+5.0%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro